Novavax (NVAX) Shares are Up 2.28%

Novavax (NVAX) has been under a strong bear grip, hence the stock is down -1.71% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.95% in the past 1 week. The stock has risen by 2.28% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.91% in the past 4 weeks.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 1.23% and the fifty day Moving Average is 0.87%. Novavax, Inc. is up 22.53% in the last three month period. Year-to-Date the stock performance stands at -14.42%.

Novavax (NVAX) : The most positive equity analysts on Novavax (NVAX) expects the shares to touch $17, whereas, the least positive believes that the stock will trade at $6 in the short term. The company is covered by 5 Wall Street Brokerage Firms. The average price target for shares are $12.98 with an expected fluctuation of $4.24 from the mean.


Novavax (NASDAQ:NVAX): stock turned positive on Friday. Though the stock opened at $7.2, the bulls momentum made the stock top out at $7.29 level for the day. The stock recorded a low of $7.04 and closed the trading day at $7.18, in the green by 4.51%. The total traded volume for the day was 5,417,793. The stock had closed at $6.87 in the previous days trading.

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *